Copyright
©The Author(s) 2015.
World J Respirol. Mar 28, 2015; 5(1): 17-27
Published online Mar 28, 2015. doi: 10.5320/wjr.v5.i1.17
Published online Mar 28, 2015. doi: 10.5320/wjr.v5.i1.17
Table 3 Summary of manuscripts of the use of portable monitoring in specific population
Ref. | Year | Population | Sample size | Device | Protocol |
Morales et al[24] | 2012 | Elderly mean age 71.4 yr | 452 | Rescare AutosetTM (ResMed, Sydney, Australia) | PM at home PSG at sleep lab |
Polese et al[22] | 2013 | Elderly > 65 yr | 43 | Stardust II® (Phillips Respironics, Inc., Murrysville, PA, United States) | PM home PM + PSG at sleep lab |
Goodwin et al[31] | 2001 | Children 5 to 12 yr | 157 | Compumedics PS-2 System (Abbotsford, Victoria, Australia) | PM at home |
Zucconi et al[32] | 2003 | Children 3 to 6 yr | 12 | POLY-MESAM; MAP; Martinsried, Germany | PSG at sleep lab PM at sleep lab |
Poels et al[30] | 2003 | Children 2 to 7 yr | 24 | Embletta PDS; Flaga hf Medical Devices, Reykjavik, Iceland) | PM at home |
Rosen et al[35] | 2003 | Children 8 to 11 yr | 55 | PT-2 System SensorMedics, Yorba Linda, California, United States | PM home PSG lab |
Alvarez et al[34] | 2008 | Children 2 to 14 yr | 53 | Edentec Monitoring System (Edentrace II, Model 3711; Edentec Corporation, Nellcor Puritan Bennett, Eden Prairie, Minnesota, United States) | PSG + PM at sleep lab |
Sardón Prado et al[37] (abstract) | 2006 | Children | 132 | Not informed | PM at hospital PM at home |
Amorim et al[38] (abstract) | 2004 | Children Mean age 10.6 yr | 31 | Not informed | PM at home |
Quintana-Gallego et al[50] | 2004 | Heart failure LVEF ≤ 45% | 75 | Apnoescreen II; Erich Jaeger Gmbh and CoKg, Wuerzburg, Germany | PSG at sleep lab PM at home |
Abraham et al[51] | 2006 | Heart failure LVEF ≤ 35% | 50 | ClearPath System Nx-301; Nexan Inc, Alpharetta, GA | PSG + PM at sleep lab PM at home |
Smith et al[52] | 2007 | Heart failure LVEF ≤ 45% | 20 | Embletta; Flaga, Iceland | PSG + PM at sleep lab PM at home |
Takama et al[57] | 2010 | CAD patients | 83 | Morpheus; Compumedics, Melbourne, Australia | PSG + PM at sleep lab |
Danzi-Soares et al[58] | 2011 | CAD patients | 79 | Stardust II, Respironics Inc., Murrysville, Pennsylvania, United States | PSG + PM at sleep lab |
Oliveira et al[68] | 2012 | COPD patients | 72 | Stardust II® (Phillips Respironics, Inc., Murrysville, PA, United States) | PSG + PM at sleep lab PM at home |
Lesser et al[78] | 2012 | Obese pediatric patients (9-18 yr ) | 25 | ApneaLink Plus (PesMed Corporation, Poway, CA) | PSG + PM at sleep lab |
Fredheim et al[79] (abstract) | 2014 | Morbidly obese patients | 105 | ApneaLink | PM PM + Embletta |
Oliveira et al[80] | 2014 | Obese patients | 58 | Stardust II® (Phillips Respironics, Inc., Murrysville, PA, United States) | PSG + PM at sleep lab PM at home |
- Citation: Treptow E, Oliveira MG, Moreira GA, Togeiro S, Nery LE, Tufik S, Bittencourt L. Update on the use of portable monitoring system for the diagnosis of sleep apnea in specific population. World J Respirol 2015; 5(1): 17-27
- URL: https://www.wjgnet.com/2218-6255/full/v5/i1/17.htm
- DOI: https://dx.doi.org/10.5320/wjr.v5.i1.17